In both trials, dapagliflozin reduced the incidence of the primary composite endpoint of CV death, hospitalization for heart failure or urgent heart failure visit in the overall population (see Table 20)
A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity Long-term Success of GLP-1s Hinges on More Than Just a Prescription A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 518% in clinical trials, along with increased metabolism and benefits to their overall heart health
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice
FDA approves Wegovy for cardiovascular risk reduction
The clinical-stage company emerged from stealth in April with $290 million in financing, led by ARCH Venture Partners
Retatrutide is being studied as a next-generation medication that targets three hormone pathways involved in appetite, metabolism, blood sugar regulation, and energy balance
